Stockscreener 앱 받기
0.53
0.95%
0.005
시간 외 거래:
.53
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World
Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria
CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus
Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com
CeroTherapeutics (CERO) Receives Buy Rating from Maxim Analyst | CERO Stock News - GuruFocus
Cero Therapeutics (CERO) Gains Buy Rating with Innovative T-Cell Therapy | CERO Stock News - GuruFocus
CERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% – Here’s What Happened - Defense World
CERO THERAPEUTICS HOLDINGS, INC. SEC 10-Q Report - TradingView
Pre-market Movers: LUCY, ALUR, PLRZ, AXDX... - RTTNews
CERo Therapeutics regains Nasdaq compliance - MSN
CERo Therapeutics Regains Nasdaq Compliance with Stockholder Equity - TipRanks
CERo Therapeutics regains Nasdaq compliance, eyes trials - Investing.com Australia
CERo Therapeutics regains Nasdaq compliance, eyes trials By Investing.com - Investing.com South Africa
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) - The Manila Times
CERo Therapeutics Regains Compliance with Nasdaq Listing Rule Following Successful Fundraising Efforts - Nasdaq
CERo Therapeutics Holdings Inc (NASDAQ: CERO): Blank Check On Growth? - Stocksregister
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - ADVFN
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia
CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq
Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com
CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire
Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan
CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com
CERo Therapeutics announces up to $8M Series D financing; shares up - MSN
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com
New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com
A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com
CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com
CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire
Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan
Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News
CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX
Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX
CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World
CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga
CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com
CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - The Manila Times
CERo Therapeutics Announces Clinical Trial Partnership with Sarah Cannon Research Institute for Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia - Nasdaq
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire
Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia
CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa
What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister
CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq
D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Boral Capital sets Cero Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
CERo Therapeutics secures $8 million in funding for cancer therapy - Investing.com Australia
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing - The Manila Times
17.27%
1.06%
자본화:
|
볼륨(24시간):